Unlocking Precision: How Nickel-64 Serves as the Key Precursor for Cancer-Targeting Copper-64

BY Tao, Published Dec 14, 2025

 

 

With more enquiries on Nickel-64 Isotope from web, I would like to share my production experience and operation these year to more end users who are interested. I have witnessed firsthand how the careful selection of a starting isotope can dramatically influence the success of targeted cancer therapies. Today, one of the most promising and clinically relevant examples is the use of Nickel-64 (⁶⁴Ni) as the primary precursor for producing Copper-64 (⁶⁴Cu), a versatile positron-emitting radionuclide that has become a cornerstone of modern theranostic cancer imaging and treatment.

In this comprehensive article, I will explain the scientific rationale, production pathways, chemical and nuclear advantages, and clinical significance of this pair, while highlighting why ⁶⁴Ni is currently the gold-standard precursor for high-purity, high-specific-activity ⁶⁴Cu.

Why Copper-64 Matters in Cancer Theranostics

Copper-64 is unique among medical radionuclides because it decays by three competing pathways:

• β⁺ emission (17.9%, E_max = 0.653 MeV) → ideal for PET imaging
• β⁻ emission (38.5%, E_max = 0.579 MeV) → suitable for targeted radionuclide therapy
• Electron capture (43.6%) → produces diagnostic gamma rays at 1346 keV

This dual decay profile allows ⁶⁴Cu to serve as a true theranostic radionuclide: the same molecule can be used for both diagnosis (PET imaging) and therapy, enabling physicians to select patients who will benefit from treatment and monitor response in real time.

The half-life of 12.7 hours is long enough for centralized production and distribution, yet short enough to minimize patient radiation exposure. These properties have made ⁶⁴Cu-labeled somatostatin analogs, PSMA ligands, antibodies, and nanoparticles the subject of hundreds of clinical trials worldwide.

The Challenge of Producing High-Purity Copper-64

Despite its clinical promise, ⁶⁴Cu production has historically been limited by the availability of high-purity precursor material and the need to achieve high specific activity (typically >10 Ci/μmol or >370 GBq/μmol).

The most widely used production route is the ⁶⁴Ni(p,n)⁶⁴Cu reaction, in which a highly enriched ⁶⁴Ni target is bombarded with protons in a medical cyclotron. This method offers several key advantages:

• High cross-section (~600 mb at 12–15 MeV)
• Minimal co-production of long-lived copper isotopes (⁶⁴Cu is the dominant product)
• Excellent separation chemistry from nickel using ion-exchange or extraction chromatography

Alternative routes such as ⁶⁵Cu(p,2n)⁶⁴Cu or ⁶⁴Zn(p,n)⁶⁴Cu suffer from lower yields, higher co-production of ⁶⁷Cu or ⁶¹Cu, and poorer specific activity, making them less suitable for clinical-grade production.

Why Nickel-64 Is the Ideal Precursor

Nickel-64 is the most abundant stable isotope of natural nickel (1.14%), yet for medical applications we require >99.5% enrichment. This high enrichment is critical for three reasons:

1. Maximized yield per target mass
   Only ⁶⁴Ni undergoes the (p,n) reaction to produce ⁶⁴Cu. Lower enrichment means more target material is needed for the same yield, increasing cost and target thickness.
2. Reduced co-production of unwanted radionuclides
   Natural nickel contains ⁵⁸Ni, ⁶⁰Ni, ⁶¹Ni, and ⁶²Ni. Proton bombardment of these isotopes produces ⁶¹Cu, ⁶⁰Cu, ⁵⁹Ni, and other contaminants that can degrade image quality or increase patient dose.
3. Improved specific activity
   Because the target is almost pure ⁶⁴Ni, the ⁶⁴Cu produced is virtually free of stable copper carrier, resulting in specific activities that routinely exceed 1000 GBq/μmol—essential for labeling small molecules and peptides with low receptor density.

The Production Process Step-by-Step

1. Target preparation
   Highly enriched ⁶⁴Ni (>99.5%) is electroplated as a thin layer (typically 50–100 mg/cm²) onto a gold or silver backing to withstand high beam currents (up to 300 μA).
2. Proton irradiation
   Cyclotron bombardment at 12–18 MeV for 2–12 hours, depending on desired activity (typically 10–50 GBq per run).
3. Chemical separation
   After a short cooldown, the target is dissolved in dilute HCl. Copper-64 is selectively separated from nickel using anion-exchange resin (AG1-X8) or chelating resins such as Cu-specific resins. Final purification often employs a second column or extraction chromatography.
4. Quality control
   Radionuclidic purity (>99.9% ⁶⁴Cu), chemical purity, and specific activity are verified by gamma spectroscopy, ICP-MS, and titration.

Commercial facilities such as the University of Wisconsin, the University of Missouri Research Reactor (MURR), and several European and Asian cyclotron centers now routinely produce clinical-grade ⁶⁴Cu from enriched ⁶⁴Ni targets.

 

 

Supply Chain and Future Outlook

The global demand for enriched ⁶⁴Ni has grown exponentially. Leading suppliers now offer ⁶⁴Ni at >99.8% enrichment with consistent quality. Advances in electromagnetic isotope separation (EMIS) and laser isotope separation promise even higher enrichment and lower cost in the coming years.

Meanwhile, next-generation cyclotrons with higher beam currents and automated targetry are pushing production capacity toward several hundred GBq per run, making ⁶⁴Cu accessible to more hospitals.

Conclusion

Nickel-64 is not merely a precursor—it is the enabling technology that unlocks the full diagnostic and therapeutic potential of Copper-64. By providing the purest possible starting material, enriched ⁶⁴Ni ensures high specific activity, low contamination, and reliable supply, all of which are essential for translating promising theranostic agents from the laboratory to the clinic.

As we continue to refine production methods and expand clinical indications, the ⁶⁴Ni → ⁶⁴Cu pathway will remain the backbone of copper-based precision oncology for years to come.

 

Would you like a deeper dive into any specific technical parameters or applications?

As an industry leader focused in isotope products, our goal is to support our customers by keeping them at the forefront of their industries. We’re here to help with any questions you might have so you can transform your ideas into reality, and tackle those big science challenges.

Get free consultant, our experts are ready to serve.

(Follow up our update articles on www.asiaisotopeintl.com or send your comments to tao.hu@asiaisotope.com for further communications)